Telacebec (Q203), a New Antituberculosis Agent
- 26 March 2020
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (13), 1280-1281
- https://doi.org/10.1056/NEJMc1913327
Abstract
Telacebec (Q203) is a novel drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. This proof-of-concept study evaluated the bactericidal activity of telacebec over a period of 14 days in patients with newly diagnosed, drug-susceptible pulmonary tuberculosis.Funding Information
- Korea Drug Development Fund
This publication has 4 references indexed in Scilit:
- Discovery of Q203, a potent clinical candidate for the treatment of tuberculosisNature Medicine, 2013
- Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patientsThe International Journal of Tuberculosis and Lung Disease, 2011
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- The Chemotherapy of Pulmonary Tuberculosis: A ReviewSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1979